Key result
The mRNA-1273 vaccine elicited a SARS-CoV-2 antibody response of 71.8 g/mL (95% CI, 58.1-88.8) compared to age-similar peers receiving BNT162b2 (95% CI, 48.8-71.4 g/mL).
Why the study?
Does the BNT162b2 vaccine produce a different SARS-CoV-2 antibody response compared to the mRNA-1273 vaccine?
Does the BNT162b2 vaccine produce a different SARS-CoV-2 antibody response compared to the mRNA-1273 vaccine?
The study compares the SARS-CoV-2 antibody response between recipients of the BNT162b2 and mRNA-1273 vaccines.
Antibody differences may guide future vaccine strategies; leaves open correlation with clinical protection.
g/mL [95% CI, 48.8-71.4 g/mL]) and age-similar peers who received mRNA-1273 (71.8 g/mL [95% CI, 58.1-88.8 g/mL]) (Figure).
No takes yet. Share an insight, caveat, or question.
Richards et al. (2021) studied this question. The mRNA-1273 vaccine elicited a SARS-CoV-2 antibody response of 71.8 g/mL (95% CI, 58.1-88.8) compared to age-similar peers receiving BNT162b2 (95% CI, 48.8-71.4 g/mL).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: